{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:08:10Z","timestamp":1787497690436,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["71003Y3035"],"award-info":[{"award-number":["71003Y3035"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.leukres.2026.108187","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:26:42Z","timestamp":1770395202000},"page":"108187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis"],"prefix":"10.1016","volume":"163","author":[{"given":"Guanghui","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-9887","authenticated-orcid":false,"given":"Feifei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108187_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.leukres.2026.108187_bib2","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1002\/cam4.5459","article-title":"Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy","volume":"12","author":"Laloi","year":"2023","journal-title":"Cancer Med"},{"issue":"20","key":"10.1016\/j.leukres.2026.108187_bib3","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108187_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108187_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108187_bib6","unstructured":"[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023). 2023. Zhonghua Xue Ye Xue Za Zhi 44 (9): 705-712."},{"issue":"13","key":"10.1016\/j.leukres.2026.108187_bib7","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.leukres.2026.108187_bib8","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428194.2020.1867724","article-title":"Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country","volume":"62","author":"Senapati","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2026.108187_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.leukres.2026.108187_bib10","first-page":"10","article-title":"Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study","volume":"9","author":"Yamada","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108187_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-4-46","article-title":"A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Wei","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108187_bib12","unstructured":"Wang, J., Jiang, B., Jiang, Q. et al. 2016. [Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen. Zhonghua Xue Ye Xue Za Zhi 37 (3): 194-200."},{"issue":"12","key":"10.1016\/j.leukres.2026.108187_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108187_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.16745","article-title":"The loss or absence of minimal residual disease of <0\u00b71% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis","volume":"192","author":"Duan","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108187_bib15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.18585","article-title":"The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation","volume":"200","author":"Luo","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108187_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3256","article-title":"Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis","volume":"42","author":"Wang","year":"2024","journal-title":"Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108187_bib17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2026.108187_bib18","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Azacitidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2026.108187_bib19","doi-asserted-by":"crossref","unstructured":"Ikoma, Y., Nakamura, N., Kaneda, Y. et al. 2025. Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax\/azacitidine for AML. Leukemia.","DOI":"10.1038\/s41375-025-02625-3"},{"key":"10.1016\/j.leukres.2026.108187_bib20","doi-asserted-by":"crossref","unstructured":"Lu, J., Xue, S., Wang, Y. et al. 2025. Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML. Blood.","DOI":"10.1182\/blood.2024027217"},{"issue":"1","key":"10.1016\/j.leukres.2026.108187_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2026.108187_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.leukres.2026.108187_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2026.108187_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"24","key":"10.1016\/j.leukres.2026.108187_bib25","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1158\/1078-0432.CCR-22-2664","article-title":"TP53 or Not TP53: That Is the Question","volume":"28","author":"Green","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.leukres.2026.108187_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040586","article-title":"Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed\/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients","volume":"17","author":"Wang","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.leukres.2026.108187_bib27","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2026.108187_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"14","key":"10.1016\/j.leukres.2026.108187_bib29","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/cncr.35278","article-title":"Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis","volume":"130","author":"Huang","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2026.108187_bib30","unstructured":"Yu, W.J., Jia, J.S., Wang, J. et al. 2022. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience. Zhonghua Xue Ye Xue Za Zhi 43 (2): 134-140."},{"key":"10.1016\/j.leukres.2026.108187_bib31","unstructured":"Mi, R.H., Chen, L., Wang, L. et al. 2023. [Retrospective analysis of the efficacy and safety of Venetoclax-based regimen in the treatment of 12 cases of acute myeloid leukemia with t (8; 21). Zhonghua Xue Ye Xue Za Zhi 44 (6): 501-504."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:44:12Z","timestamp":1777488252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"alternative-id":["S0145212626000317"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108187","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108187"}}